Mitsubishi Tanabe Pharma Corporation

Type: Company
Name: Mitsubishi Tanabe Pharma Corporation
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Mitsubishi Tanabe's Hep C Drug Cited For 15 Deaths Since Japan Launch

Related Biotechnology, Pharmaceutical and Healthcare NewsMitsubishi Tanabe Pharma's Teravic (peginterferon/ribavirin) hepatitis C drug has been cited as the cause of 15 deaths and more than 2,500 severe side effects in Japan since its 2011 launch, according ... [Published BioPortfolio - Jul 28 2014]
First reported Jul 27 2014 - Updated Jul 27 2014 - 1 reports

15 die after taking Mitsubishi Tanabe Hepatitis C Drug

Fifteen people have died, and more than 2,500 suffered severe side effects, after taking Teravic — a hepatitis C drug produced by Mitsubishi Tanabe Pharma Corp., it was learned Saturday.Most of the dead had been suffering from cirrhosis of the liver, ... [Published Japan Times - Jul 27 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Mitsubishi receives approval to manufacture and market diabetes drug

Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd. have announced that Mitsubishi has received approval to manufacture and market the SGLT2 inhibitor, CANAGLU tablets 100mg in Japan, for the treatment of patients with type 2 diabetes mellitus. ... [Published Individual.com - Jul 14 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 1 reports

Dezima Pharma Extends Clinical Development Program For Its CETP Inhibitor TA-8995

7/9/2014 9:17:58 AMPhase 2b TULIP study readout in August 2014, new Lipoprotein(a) study approvedNaarden, The Netherlands, 9 July 2014 – Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, today ... [Published BioSpace - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

VIVUS Inc. (VVUS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Summary:We are initiating coverage on VIVUS with an Outperform recommendation and a target price of $6.00. In the first quarter of 2014, VIVUS reported a loss of $0.13 per share, much narrower than the Zacks Consensus Estimate of a loss of $0.34 and the ... [Published Zacks.com - Jul 08 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 1 reports

Marketing and Manufacturing Approval in Japan Received for CANAGLU® Tablets 100mg

Mitsubishi Tanabe Pharma CorporationDaiichi Sankyo Co., Ltd. Osaka and Tokyo, Japan, July 4, 2014-Mitsubishi Tanabe Pharma Corporation (hereafter, Mitsubishi Tanabe Pharma; Head Office: Chuo-ku, Osaka; President & Representative Director, CEO: Masayuki ... [Published Noodls - Jul 04 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Sawai Pharmaceutical Co Ltd to take over business from subsidiary of Tanabe Pharma Corporation

8:30am BST Sawai Pharmaceutical Co Ltd:Signed basic agreement with Mitsubishi Tanabe Pharma Corporation on June 30, concerning transfer pharmaceutical manufacturing business of Kashima Plant that belongs to its wholly owned subsidiary Mitsubishi Tanabe ... [Published Reuters UK - Jun 30 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

IPO Report: Minerva Neuroscience (NERV)

Minerva Neurosciences   ($NERV) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system, or CNS, diseases. It is headquartered ... [Published Equities.com - Jun 25 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

Surveyed U.S. Psychiatrists Would Prescribe EnVivo Pharmaceuticals' Encenicline to 25 Percent of their Patients with Cognitive Impairment Associated with Schizophrenia

BURLINGTON, Mass., March 31, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. psychiatrists would prescribe EnVivo Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma's encenicline to 25 percent of their patients with cognitive ... [Published PR Newswire: General Business - Mar 31 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 1 reports

Find Your Next Asia Partnership in Tokyo at BIO Asia

On April 8-9, 2014, the  BIO Asia International Conference  will enter its eleventh year. This year, bioparma industry leaders will convene at the Grand Hyatt in Tokyo, Japan to make the cross border deals that will advance collaboration between Asia ... [Published I Am Biotech - Mar 12 2014]

Quotes

Original Article: NEXT ARTICLE More From BioPortfolio on "Mitsubishi Tanabe's Hep C Drug Cited For 15 Deaths Since Japan Launch"
...health care," stated Timothy E Morris, senior vice president, finance and global commercial development, chief financial officer for VIVUS Inc. "We look forward to working with Auxilium as they prepare for launch later this year."

More Content

All (14) | News (10) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (2) | Press Releases (0)
sort by: Date | Relevance
Mitsubishi Tanabe's Hep C Drug Cited For 15 Dea... [Published BioPortfolio - Jul 28 2014]
15 die after taking Mitsubishi Tanabe Hepatitis... [Published Japan Times - Jul 27 2014]
Mitsubishi receives approval to manufacture and... [Published Individual.com - Jul 14 2014]
Dezima Pharma Extends Clinical Development Prog... [Published BioSpace - Jul 09 2014]
VIVUS Inc. (VVUS): New Analyst Report from Zack... [Published Zacks.com - Jul 08 2014]
Marketing and Manufacturing Approval in Japan R... [Published Noodls - Jul 04 2014]
Sawai Pharmaceutical Co Ltd to take over busine... [Published Reuters UK - Jun 30 2014]
IPO Report: Minerva Neuroscience (NERV) [Published Equities.com - Jun 25 2014]
Surveyed U.S. Psychiatrists Would Prescribe EnV... [Published PR Newswire: General Business - Mar 31 2014]
Find Your Next Asia Partnership in Tokyo at BIO... [Published I Am Biotech - Mar 12 2014]
Global Over-the-counter (OTC) Pharmaceutical Ma... [Published GlobeNewswire - Nov 21 2013]
Auxilium Pharma to market VIVUS's ED drug, Sten... [Published PharmaBiz - Oct 14 2013]
Fact Sheet for Mitsubishi Chemical Holdings Corp [Published Silobreaker - Feb 05 2010]
Fact Sheet for Mitsubishi Chemical Holdings Cor... [Published Able2Act - Dec 28 2007]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Surveyed U.S. Psychiatrists Would Prescribe EnV... [Published PR Newswire: General Business - Mar 31 2014]
BURLINGTON, Mass., March 31, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. psychiatrists would prescribe EnVivo Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma's encenicline to 25 percent of their patients with cognitive ...
Find Your Next Asia Partnership in Tokyo at BIO... [Published I Am Biotech - Mar 12 2014]
On April 8-9, 2014, the  BIO Asia International Conference  will enter its eleventh year. This year, bioparma industry leaders will convene at the Grand Hyatt in Tokyo, Japan to make the cross border deals that will advance collaboration between Asia ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.